Market Segmentation
By Treatment Type
- Chemotherapy
- Targeted drug therapy
- Immunotherapy
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel,
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The current market size of the brain cancer industry is USD 2.9 billion in 2023.
Rising prevalence of brain tumors, Improving diagnosis and screening rates, Emergence of novel therapies like immunotherapy, targeted drugs, Rising healthcare expenditure and research funding, Increasing geriatric population, Advances in radiation therapy and surgical techniques
Low awareness in developing regions, High cost of therapies, Stringent regulations for drug approval, Failure of many clinical trials, Adverse effects of radiation and chemotherapy
Gliomas are the leading tumor type segment in the brain cancer market.
Hoffmann-La Roche, AbbVie, Amgen, Merck & Co., Bristol-Myers Squibb, Novocure, Varian Medical Systems, Elekta, Accuray, Ion Beam Applications, Brainlab.
The market is expected to grow at a CAGR of 7.8% from USD 2.9 billion in 2023 to USD 4.9 billion by 2030.
Rising prevalence and incidence rates, Improved diagnosis and screening tools, Emerging targeted therapies and immunotherapies, Rising healthcare spending and research funding, Advances in radiation therapy and surgical techniques, Growing geriatric population.